Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination.
The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed.
Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur’s lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectable …
Full story available on Benzinga.com
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination.
The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed.
Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur’s lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectable …
Full story available on Benzinga.com
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination.
The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed.
Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur’s lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectable …Full story available on Benzinga.com Read MoreBiotech, Briefs, DECA, News, Opioid, SCLX, SPACs, Stories That Matter, Health Care, IPOs, Top Stories, Movers, Trading Ideas, General, SCLX, DECA, News, Biotech, Health Care, IPOs, Top Stories, Movers, Trading Ideas, General, Benzinga IPOs
